Your browser doesn't support javascript.
loading
Effectiveness and Safety of Apixaban versus Warfarin in Venous Thromboembolism Patients with Chronic Kidney Disease.
Cohen, Alexander T; Sah, Janvi; Dhamane, Amol D; Lee, Theodore; Rosenblatt, Lisa; Hlavacek, Patrick; Emir, Birol; Delinger, Rachel; Yuce, Huseyin; Luo, Xuemei.
Afiliação
  • Cohen AT; Department of Hematological Medicine, Guy's & St. Thomas' NHS Foundation Trust, King's College London, London, United Kingdom.
  • Sah J; SIMR, LLC, Ann Arbor, Michigan, United States.
  • Dhamane AD; Bristol Myers Squibb Company, Lawrenceville, New Jersey, United States.
  • Lee T; Pfizer Inc., New York, New York, United States.
  • Rosenblatt L; Bristol Myers Squibb Company, Lawrenceville, New Jersey, United States.
  • Hlavacek P; Pfizer Inc., New York, New York, United States.
  • Emir B; Pfizer Inc., New York, New York, United States.
  • Delinger R; SIMR, LLC, Ann Arbor, Michigan, United States.
  • Yuce H; Department of Mathematics, New York City College of Technology, City University of New York, New York, New York, United States.
  • Luo X; Pfizer Inc., Groton, Connecticut, United States.
Thromb Haemost ; 122(6): 926-938, 2022 Jun.
Article em En | MEDLINE | ID: mdl-34963185
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Insuficiência Renal Crônica / Tromboembolia Venosa / Falência Renal Crônica Tipo de estudo: Diagnostic_studies / Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Insuficiência Renal Crônica / Tromboembolia Venosa / Falência Renal Crônica Tipo de estudo: Diagnostic_studies / Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article